Bionics

Worldwide Artificial Organ and Bionics Industry to 2025 - Advantageous in Comparison Prosthetics Presents Opportunities

Tuesday, April 13, 2021 - 7:15pm

This has been a major boost for the artificial organ bionics market, as the patients cannot afford to wait in queue since the stakes are very high.

Key Points: 
  • This has been a major boost for the artificial organ bionics market, as the patients cannot afford to wait in queue since the stakes are very high.
  • Bionics and artificial organs are able to cater to the needs of those in need of organ transplantations and replacements.
  • In February 2020, Ekso Bionics Holdings, Inc. collaborated with Kindred Healthcare, LLC to pilot EksoNR - a robotic exoskeleton, in their long-term acute care hospitals.\n2.
  • In April 2019, Edwards Lifesciences Corporation acquired CAS Medical Systems, Inc., a medical technology company dedicated to non-invasive brain and tissue oxygenation monitoring.\n3.

Global Artificial Organ and Bionics Market (2020 to 2025) - by Type, Technology, End-user and Geography - ResearchAndMarkets.com

Thursday, April 8, 2021 - 1:48pm

In February 2020, Ekso Bionics Holdings, Inc. collaborated with Kindred Healthcare, LLC to pilot EksoNR - a robotic exoskeleton, in their long-term acute care hospitals.

Key Points: 
  • In February 2020, Ekso Bionics Holdings, Inc. collaborated with Kindred Healthcare, LLC to pilot EksoNR - a robotic exoskeleton, in their long-term acute care hospitals.
  • In April 2019, Edwards Lifesciences Corporation acquired CAS Medical Systems, Inc., a medical technology company dedicated to non-invasive brain and tissue oxygenation monitoring.
  • The report offers a comprehensive evaluation of the Global Artificial Organ and Bionics Market.
  • The report also contains the competitive analysis using IGR Competitive Quadrant, the analyst's proprietary competitive positioning tool.

Second Sight Medical Products Names Dean Baker and Alexandra Larson to its Board of Directors

Tuesday, April 6, 2021 - 1:00pm

Second Sight Medical Products, Inc. (NASDAQ: EYES) (the Company or Second Sight), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that the Companys Board of Directors has appointed two new members, Dr. Dean Baker and Ms. Alexandra Larson.

Key Points: 
  • Second Sight Medical Products, Inc. (NASDAQ: EYES) (the Company or Second Sight), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that the Companys Board of Directors has appointed two new members, Dr. Dean Baker and Ms. Alexandra Larson.
  • Dr. Baker serves on the Board of Directors of Nano Precision Medical and served on the Board of Directors of Advanced Bionics prior to its sale to Boston Scientific.
  • He currently serves on the Board of Directors for Transonic Imaging, a medical imaging startup.
  • About Second Sight Medical Products, Inc.
    Second Sight Medical Products, Inc. (Nasdaq: EYES) develops and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.

Ottobock North America Appoints MedTech Industry Leader Marc C. Lundeberg as CEO & Regional President

Tuesday, March 30, 2021 - 10:20pm

AUSTIN, Texas, March 30, 2021 /PRNewswire/ --Today, Ottobock and its Board of Directors announced the appointment of Marc C. Lundeberg as the new CEO and Regional President of the company's North America operation.

Key Points: 
  • AUSTIN, Texas, March 30, 2021 /PRNewswire/ --Today, Ottobock and its Board of Directors announced the appointment of Marc C. Lundeberg as the new CEO and Regional President of the company's North America operation.
  • Effective February 1, 2021, Marc succeeds Brad Ruhl, who will remain on as Non-Executive Chairman until he transitions to retirement after a more than 30-year tenure with Ottobock.
  • Lundeberg joins Ottobock North America from Amplifon, where he held the position of CEO & President for North America, since May 2017.
  • Ottobock has been investing, employing, researching and developing in North America since 1958 for the benefit of people with impaired mobility.

First Four Patients In Bionic Sight’s Optogenetic Gene Therapy Trial Are Able To Detect Light And Motion

Tuesday, March 30, 2021 - 12:00pm

The patients, all of whom have complete or near-complete blindness, can now see light and motion, and, in two cases, can detect the direction of motion.

Key Points: 
  • The patients, all of whom have complete or near-complete blindness, can now see light and motion, and, in two cases, can detect the direction of motion.
  • For the latter, the patients were asked to look into a device, similar to a virtual reality device, and distinguish among presented stimuli (e.g., light vs. no light, leftward motion vs rightward motion).
  • Bionic Sights Phase 1/2 trial (ClinicalTrials.gov identifier: NCT04278131 ) is an open-label, dose escalation study in patients with advanced-stage RP.
  • BIONIC SIGHT is a biotech company that develops optogenetic gene therapy vectors and devices to treat retinal degenerative diseases.

Ekso Bionics Announces Partnership with U.S. Physiatry to Support Physician Education of EksoNR

Tuesday, March 9, 2021 - 1:00pm

The partnership will help expand awareness of Ekso Bionics technology among physicians and other rehabilitation clinicians as well as educate on how to successfully implement robotics into a rehabilitation program.

Key Points: 
  • The partnership will help expand awareness of Ekso Bionics technology among physicians and other rehabilitation clinicians as well as educate on how to successfully implement robotics into a rehabilitation program.
  • Topics will include EksoNR education, research and development, best practices on Ekso program implementation, and general marketing of an EksoNR.
  • Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO.
  • To learn more about Ekso Bionics please visit the Companys website at www.eksobionics.com or follow @EksoBionics on Twitter.

Cochlear Implant System Market Revenue to Cross USD 2.2B by 2027: Global Market Insights, Inc.

Thursday, February 25, 2021 - 9:00am

SELBYVILLE, Del., Feb. 25, 2021 /PRNewswire/ --According to the latest report "Cochlear Implant System Market by Product (Unilateral Implant, Bilateral Implant), End-user (Adult, Pediatric), Regional Outlook, Price Trends, Competitive Market Share & Forecast 2027", by Global Market Insights, Inc., the market valuation of cochlear implant systems will cross $2.2 billion by 2027.

Key Points: 
  • SELBYVILLE, Del., Feb. 25, 2021 /PRNewswire/ --According to the latest report "Cochlear Implant System Market by Product (Unilateral Implant, Bilateral Implant), End-user (Adult, Pediatric), Regional Outlook, Price Trends, Competitive Market Share & Forecast 2027", by Global Market Insights, Inc., the market valuation of cochlear implant systems will cross $2.2 billion by 2027.
  • For instance, in December 2020, Advanced Bionics that collaborated with Phonak received the U.S. FDA approval for their cochlear implant product.
  • The increasing prevalence of hearing loss and impairment will contribute to the cochlear implant system market demand.
  • The pediatric segment in the cochlear implant system market accounted for USD 580 million in 2020.

Bionic Vision Technologies Advances Clinical Program With AU$1 million Medical Research Future Fund Grant

Wednesday, February 17, 2021 - 12:03am

BVT's bionic eye is designed for people with the inherited retinal disease retinitis pigmentosa for which there is no current cure.

Key Points: 
  • BVT's bionic eye is designed for people with the inherited retinal disease retinitis pigmentosa for which there is no current cure.
  • Clinical study data from patients implanted with the device show the prosthesis is safe and gives significant improvements to functional vision and quality of life.
  • The Melbourne-based Australian medical technology start-up received AU$1million from the Medical Research Future Fund's BioMedTech Horizons 3.0 program in late 2020.
  • The Medical Research Future Fund's BioMedTech Horizon's program supports new medical technologies and is focused on digital applications in medical devices and personalised medicine.

Beta Bionics Announces the Appointment of Martha Goldberg Aronson as Chair of Its Board of Directors

Tuesday, February 9, 2021 - 9:01pm

Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet bionic pancreas system, today announced the appointment of Martha Goldberg Aronson as Chair of its Board of Directors, effective immediately.

Key Points: 
  • Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet bionic pancreas system, today announced the appointment of Martha Goldberg Aronson as Chair of its Board of Directors, effective immediately.
  • Ms. Aronson, who joined the Beta Bionics Board as a Director in February of 2020, succeeds Ed Damiano, President and Chief Executive Officer of Beta Bionics, who has served as Chair since inception of the company in 2015.
  • On behalf of the Board, I am pleased to welcome Martha into the role of Chair, commented Ed Damiano, President and Chief Executive Officer.
  • It has been a great honor to have served as Chair of the Beta Bionics Board of Directors over the past five years, and Im looking forward to continuing to work closely with Martha and the Board.

Sensorion Announces Preclinical Data Demonstrating SENS-401’s Potential to Preserve Residual Hearing After Cochlear Implantation

Tuesday, January 19, 2021 - 6:30am

But preserving acoustic hearing in patients with less severe forms of hearing loss who receive cochlear implants could provide a substantial benefit to this population, said Nawal Ouzren, CEO of Sensorion.

Key Points: 
  • But preserving acoustic hearing in patients with less severe forms of hearing loss who receive cochlear implants could provide a substantial benefit to this population, said Nawal Ouzren, CEO of Sensorion.
  • The preclinical program was conducted as part of a collaboration between Sensorion and Cochlear (ASX: COH), the global leader in implantable hearing solutions.
  • The study was designed to determine whether SENS-401 has the potential to improve preservation of residual acoustic hearing after cochlear implantation.
  • Either SENS-401 or a placebo was delivered via an eluting electrode in an established pre-clinical model of cochlear implantation.